Biocon Limited
All news and filings related to Biocon Limited.
View all news & filings- Low impact
Biocon Limited Schedules Investor Roadshow in Mumbai on September 11, 2026
Biocon Limited will hold an investor roadshow in Mumbai on September 11, 2026. The event will involve in-person one-on-one and group interactions with analysts and institutional investors. No Unpublished Price Sensitive Information will be disclosed.
Read the summary - High impact
Biocon Secures 10-Year Pertuzumab Supply Contract in Brazil
Biocon Limited secured a 10-year supply contract for Pertuzumab in Brazil via a partnership with Bahiafarma and Bionovis. The consortium received 100% allocation under Brazil's PDP program, granting exclusive access to 70% of the country's demand. Biocon will receive milestone payments and revenue share over 10 years.
Read the summary - Low impact
Biocon Limited to meet Nomura Asian Credit Corporate Day 2026 on Sep 4
Biocon Limited's management will meet with Nomura Asian Credit Corporate Day 2026 on September 4, 2026. The meeting will be held virtually. No UPSI will be disclosed.
Read the summary - Low impact
Biocon Limited announces final dividend payment of ₹0.50 per share for FY25-26
Biocon Limited has remitted its final dividend of ₹0.50 per equity share for FY25-26. The dividend was approved at the AGM on August 06, 2026. Shareholders should verify their accounts and contact the RTA for any issues.
Read the summary - Medium impact
Biocon Biologics Receives Japan MHLW Approval for Pegfilgrastim Biosimilar
Biocon Biologics received marketing approval from Japan's MHLW for its pegfilgrastim biosimilar. The product, a biosimilar to Neulasta®, will be marketed by Sandoz K.K. in Japan. This approval aims to increase global patient access to affordable medications.
Read the summary - Medium impact
Biocon Limited Receives U.S. FDA Supplemental Approval for Yesintek® Autoinjector
Biocon Limited's U.S. subsidiary received supplemental FDA approval for Yesintek® (ustekinumab-kfce) autoinjectors (45mg & 90mg). This enhances Biocon's immunology portfolio and commitment to patient access to affordable medicines.
Read the summary - Low impact
Biocon Limited Schedules Investor Meeting on August 17, 2026
Biocon Limited will attend the Motilal Oswal 22nd Annual Global Investor Conference on August 17, 2026. Management will engage in in-person one-on-one and group meetings in Mumbai. No Unpublished Price Sensitive Information will be disclosed during the event.
Read the summary - Medium impact
Biocon Limited Q1 FY27 Earnings Call Transcript Released
Biocon Limited released its Q1 FY27 earnings call transcript. The biopharmaceuticals segment grew 17% YoY, driven by biosimilars. Syngene's revenue declined 16% YoY due to client issues, but is expected to recover in H2 FY27. The company is focusing on profitable growth and expects improved performance throughout the year.
Read the summary - High impact
Biocon Limited's 48th AGM: All resolutions passed, including dividend and new incentive plan.
Biocon Limited's 48th AGM on August 06, 2026, saw all resolutions passed. Key approvals include the final dividend of 10% (₹0.50/share), appointment of a new director, and adoption of the Biocon Unity Long Term Incentive Plan 2026. The company also approved financial assistance for employee stock plans.
Read the summary - Low impact
Biocon Limited Schedules Meeting with Analyst(s)/Institutional Investor(s) on Aug 12
Biocon Limited's management will meet with analysts and institutional investors on August 12, 2026, for the Emkay Confluence 2026 event. The meeting will be conducted virtually, and no Unpublished Price Sensitive Information will be disclosed.
Read the summary - Low impact
Biocon Limited Schedules Investor Meet on August 12, 2026
Biocon Limited will meet with analysts and institutional investors on August 12, 2026, for the Emkay Confluence 2026. The interaction will be virtual, and no Unpublished Price Sensitive Information will be disclosed.
Read the summary - Low impact
Biocon Limited Q1 FY27 Financial Results Announced
Biocon Limited announced its Q1 FY27 results on August 7, 2026. The unaudited standalone and consolidated results were approved by the board on August 5, 2026. Full financial details are available on the company's website and stock exchanges.
Read the summary - Low impact
Biocon Biologics Ltd. Statutory Auditors B S R & Co. LLP Resign
B S R & Co. LLP, statutory auditors of Biocon Biologics Limited (BBL), a material subsidiary of Biocon Limited, have resigned. The resignation, effective August 6, 2026, is to align auditors with the holding company due to mandatory rotation. B S R & Co. LLP had completed audits up to March 31, 2026.
Read the summary - Medium impact
Biocon Limited: Director Re-appointment & New Auditors Appointed at 48th AGM
Biocon Limited re-appointed Mr. Eric Vivek Mazumdar as Director at its 48th AGM on August 06, 2026. S.R. Batliboi & Associates LLP was appointed as Statutory Auditors for five years, succeeding B S R & Co. LLP. Mr. Nicholas Robert Haggar completed his term as Independent Director.
Read the summary - Medium impact
Biocon Appoints S.R. Batliboi as New Auditors; Re-appoints Director Eric Mazumdar
Biocon Limited's 48th AGM on August 6, 2026, saw the re-appointment of Director Eric Vivek Mazumdar. S.R. Batliboi & Associates LLP was appointed as the new Statutory Auditors for a five-year term, replacing B S R & Co. LLP. Independent Director Nicholas Robert Haggar completed his term.
Read the summary - Low impact
Biocon Announces Director Re-appointment and New Statutory Auditors at 48th AGM
Biocon Limited's 48th AGM on August 6, 2026, saw the re-appointment of Director Mr. Eric Vivek Mazumdar. S.R. Batliboi & Associates LLP was appointed as Statutory Auditors for five years, succeeding B S R & Co. LLP. Mr. Nicholas Robert Haggar completed his term as Independent Director.
Read the summary - Medium impact
Biocon Limited Holds 48th AGM on August 6, 2026, Approves Dividend and New Incentive Plans
Biocon Limited held its 48th AGM on August 6, 2026. Shareholders approved a final dividend of 10% (₹0.50 per share) for FY2025-26. New long-term incentive plans, including stock units for employees, were also approved. S.R. Batliboi & Associates LLP was appointed as the new statutory auditor.
Read the summary - Low impact
Biocon Limited Releases Q1 FY27 Earnings Call Audio and Video Recording
Biocon Limited has released the audio and video recordings for its Q1 FY27 Earnings Call, held on August 06, 2026. The recordings are accessible via the company's website.
Read the summary - Medium impact
Biocon Limited Announces Q1 FY27 Earnings Call Presentation
Biocon Limited reported Q1 FY27 results with revenue from operations at ₹4,336 crore, up 10% YoY. Biosimilars revenue rose 16% to ₹2,855 crore, and Generics revenue increased 21% to ₹760 crore. Services revenue declined 16% to ₹736 crore. The company expects performance to strengthen in H2 FY27.
Read the summary - Low impact
Biocon Limited: Monitoring Agency Report for Q1 FY27 Shows No Deviation in QIP Fund Utilization
Biocon Limited's QIP Monitoring Agency Report for Q1 FY27 confirms no deviation in fund utilization. The company raised ₹4,150 crore in Jan 2026. Proceeds were used for Biocon Biologics acquisition, debt repayment, general corporate purposes, and issue expenses.
Read the summary - High impact
Biocon Q1FY27 Total Income at ₹4,391 Cr, Up 9%; Net Profit at ₹141 Cr
Biocon Limited reported Q1FY27 consolidated total income of ₹4,391 crore, up 9% YoY. Revenue from operations grew 10% to ₹4,336 crore, driven by Biopharma revenue up 17%. Net Profit was ₹141 crore, a 355% increase. EBITDA stood at ₹902 crore. The company also noted reduced interest costs by 23%.
Read the summary - Medium impact
Biocon Reports Q1 FY27 Unaudited Results; Board Approves Financials
Biocon Limited's Board approved unaudited standalone and consolidated financial results for Q1 FY27 (ended June 30, 2026). Consolidated profit was ₹1,368 million on total income of ₹43,905 million. Standalone profit was ₹522 million on total income of ₹6,893 million. The Board recommended a final dividend of ₹0.50 per share.
Read the summary - Medium impact
Biocon Launches Yesafili™, Biosimilar to Eylea®, in the US Market
Biocon Limited announced the U.S. commercial launch of Yesafili™ (aflibercept-jbvf), an interchangeable biosimilar to Regeneron's Eylea® 2 mg. Approved by the U.S. FDA in May 2024, Yesafili™ targets conditions like wet AMD, DME, and RVO. This launch aims to expand patient access to affordable treatments in the U.S. ophthalmology market.
Read the summary - Medium impact
Biocon Launches Yesafili , Biosimilar Aflibercept, in the US
Biocon Limited launched Yesafili , a biosimilar aflibercept, in the United States on August 3, 2026. Approved as an interchangeable biosimilar to Eylea 2 mg by the U.S. FDA in May 2024, it treats eye conditions like AMD and DME. This launch expands Biocon's ophthalmology presence.
Read the summary - Medium impact
Biocon's Yesintek® Autoinjector Pen Receives Health Canada Approval
Biocon's subsidiary in Canada received Health Canada approval for Yesintek® (ustekinumab) Autoinjector. This new format offers patients an additional treatment option for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The approval strengthens Biocon's immunology portfolio in Canada.
Read the summary - Medium impact
Biocon Announces Board Meeting for Q1 FY27 Financial Results on Aug 5
Biocon Limited will hold a Board Meeting on August 5, 2026, to approve Q1 FY27 un-audited financial results. An Earnings Conference Call for analysts and investors is scheduled for August 6, 2026, at 10:00 AM IST. The trading window will reopen on August 8, 2026.
Read the summary - Low impact
Biocon Limited: Independent Director Bobby Kanubhai Parikh Completes Second Term on July 22, 2026
Biocon Limited's Independent Director, Mr. Bobby Kanubhai Parikh, has completed his second term and ceased to be a Director effective July 22, 2026. The Board acknowledged his contributions.
Read the summary - Low impact
Biocon Announces 48th AGM and E-voting Information
Biocon Limited will hold its 48th AGM on August 06, 2026, via VC/AVM. Remote e-voting is open from August 01 to August 05, 2026. A final dividend of 10% (₹0.50 per share) was approved for FY2025-26, with payment expected by August 20, 2026, post-approval.
Read the summary - Medium impact
Biocon Malaysia Secures EMA Approval for New Insulin Fill Finish Unit
Biocon Malaysia has received EMA approval for a new insulin fill finish line for Semglee® (insulin glargine). Supplies to Europe are expected to begin from Q2FY27, enhancing Biocon's manufacturing capabilities in the region.
Read the summary - Medium impact
Biocon Limited Announces 48th AGM on Aug 6, 2026, Releases Integrated Annual Report FY26
Biocon Limited will hold its 48th AGM on August 6, 2026. The company released its Integrated Annual Report for FY26, showing total income of ₹172,695 million and EBITDA of ₹37,978 million. A final dividend of ₹0.50 per share was announced. The report details progress in biosimilars, generics, and CRDMO businesses, alongside sustainability efforts.
Read the summary - Low impact
Biocon Limited Files SEBI Compliance Certificate for Q1 FY27
Biocon Limited submitted a compliance certificate for the quarter ended June 30, 2026, as per SEBI regulations. KFin Technologies confirmed dematerialization details. This is a routine regulatory filing.
Read the summary - Medium impact
Biocon's Biosimilar Yesafili™ Data Published in Top Journals
Biocon's aflibercept biosimilar, Yesafili™, has had pivotal clinical data published in the British Journal of Ophthalmology and Expert Opinion on Biological Therapy. The studies support its effectiveness for diabetic macular edema (DME) and show comparability to reference aflibercept. This milestone aids Biocon's upcoming U.S. launch.
Read the summary - Medium impact
Biocon Completes Acquisition of Biocon Biologics Shares, Allots 87.86 Lakh Equity Shares
Biocon Limited acquired 1,15,36,956 equity shares of Biocon Biologics Limited (BBL) on June 29, 2026. It allotted 87,86,362 equity shares at ₹376.41 per share as consideration. BBL is now a wholly-owned subsidiary.
Read the summary - High impact
Biocon Acquires Full Stake in Biocon Biologics, Allots 87.86 Lakh Shares
Biocon Limited has acquired the remaining equity shares of Biocon Biologics Limited (BBL), making it a wholly-owned subsidiary. The company allotted 87,86,362 equity shares at ₹376.41 per share to 127 selling shareholders on June 29, 2026, as consideration. This increases Biocon's equity share capital.
Read the summary - Low impact
Biocon Limited: Trading Window Closure for Q1 FY27 Financial Results
Biocon Limited's trading window for shares will be closed from July 1, 2026. The closure is until 48 hours after the declaration of financial results for the quarter ending June 30, 2026. The date of the board meeting for results declaration will be announced later.
Read the summary - Medium impact
Biocon Partner Duopharma Secures MYR 225M Insulin Tenders in Malaysia
Biocon's partner, Duopharma Biotech, secured Malaysian Ministry of Health insulin tenders valued over MYR 225 million. Contracts include MYR 155.27M for human insulin, MYR 18M for insulin glargine, and MYR 52.5M for insulin aspart over three and two-year periods. Biocon's Malaysian facility will supply these therapies, reinforcing its commitment to diabetes care.
Read the summary - Medium impact
Biocon Limited: Final Dividend for FY26 & TDS Communication
Biocon Limited recommended a final dividend of 10% (₹0.50 per share) for FY26, subject to shareholder approval at the AGM on August 06, 2026. The Record Date is July 03, 2026. The company detailed TDS regulations for resident and non-resident shareholders, requiring document submission by July 20, 2026.
Read the summary - Medium impact
Biocon Acquires Stake in Ampin C&I Power Twelve for ₹5.48 Crore
Biocon Limited acquired a stake in Ampin C&I Power Twelve Private Limited for ₹5.48 crore. The investment aims to enhance renewable energy consumption and support decarbonization goals. Biocon's initial stake will be 37.77%, reducing to 15.91% post-dilution. AMPIN will set up a 27.12 MW solar plant.
Read the summary - Low impact
Biocon Limited Schedules Investor Meets on June 2, 8
Biocon Limited will host investor meets on June 2 and June 8, 2026, presenting an investor deck. The company highlights its strong financial position, with FY26 revenues at ₹17,270 crore and EBITDA at ₹3,798 crore. Efforts to improve financial metrics include a ₹4,500 crore QIP and debt refinancing.
Read the summary - Low impact
Biocon Limited: Newspaper Publishes Corrigendum to Postal Ballot Notice
Biocon Limited published a corrigendum to its postal ballot notice in Financial Express and Vijayavani on May 30, 2026. This is a regulatory compliance update.
Read the summary - Medium impact
Biocon Limited Issues Corrigendum for Preferential Issue, Adjusts Terms
Biocon Limited issued a corrigendum for its preferential issue, adjusting the floor price to ₹373.08, issue price to ₹376.41, and swap ratio to 0.76159. This involves issuing 87,86,362 shares for a consideration of ₹330.73 crore. The remote e-voting period ends on June 07, 2026.
Read the summary - Low impact
Biocon Limited to Meet with Investec US Pharma & Healthcare Bus Tour on June 3, 2026
Biocon Limited's management will meet with investors during the Investec US Pharma & Healthcare Bus Tour on June 3, 2026, in the USA. No Unpublished Price Sensitive Information (UPSI) will be disclosed during the meeting. The schedule is subject to change.
Read the summary - Low impact
Biocon sends reminder to shareholders to claim unclaimed dividends by August 20, 2026
Biocon Limited reminds shareholders to claim unclaimed dividends for seven consecutive years, particularly from FY 2018-19, to avoid transfer to the IEPF. Final dividends were declared for FYs 2018-19 (July 26, 2019), 2021-22 (July 28, 2022), 2022-23 (August 11, 2023), 2023-24 (August 9, 2024), and 2024-25 (August 8, 2025). Shareholders must claim by August 20, 2026. Unpaid dividends and shares up to FY18 have already been transferred to IEPF.
Read the summary - Low impact
Biocon Limited to Participate in Investor Conferences in June 2026
Biocon Limited will participate in the Morgan Stanley India Investment Forum on June 2, 2026, and the ICICI Securities India Investor Conference on June 8, 2026. Both events will be held in Mumbai. Management will engage in one-on-one and group interactions.
Read the summary - Low impact
Biocon Limited Releases Q4 FY26 Earnings Call Transcript
Biocon Limited released its Q4 FY26 earnings call transcript on May 14, 2026. The company reported resilient performance driven by biosimilars, with Q4 FY26 operating revenue up 10% YoY (excluding a one-time item). EBITDA stood at ₹1,073 crore. Management highlighted successful business integration and a focus on execution and value creation.
Read the summary - Medium impact
Biocon Pharma Receives Health Canada Approval for Micafungin Injection
Biocon Pharma Limited has received Health Canada approval for its micafungin for injection (50 mg and 100 mg). The drug is used to treat various Candida infections and for prophylaxis in stem cell transplant patients. This strengthens Biocon's biosimilars and generics portfolio.
Read the summary - Medium impact
Biocon Limited Announces Postal Ballot for Key Corporate Actions
Biocon Limited is conducting a postal ballot for members to approve key corporate actions. This includes changes in remuneration for Ms. Kiran Mazumdar-Shaw and appointments of new CEO & MD, Mr. Shreehas Pradeep Tambe. It also covers preferential share issuance and appointments of several new directors. Remote e-voting is open from May 9 to June 7, 2026.
Read the summary - Low impact
Biocon Limited Announces Newspaper Publication of Q4 FY26 Financial Results
Biocon Limited published its Q4 FY26 financial results in newspapers on May 09, 2026. The company is also seeking shareholder approval via postal ballot for key appointments, including Mr. Shreehas Pradeep Tambe as CEO & MD, and revisions to Ms. Kiran Mazumdar-Shaw's remuneration. Remote e-voting is open from May 9 to June 7, 2026.
Read the summary - Medium impact
Biocon Seeks Shareholder Approval for Key Appointments and Remuneration Revision
Biocon is seeking shareholder approval via postal ballot for revising Kiran Mazumdar-Shaw's remuneration to ₹21 crore annually. It also proposes appointing Shreehas Pradeep Tambe as CEO & MD and issuing 87.9 lakh shares on a preferential basis for BBL equity swap. Re-appointments and new director appointments are also on the agenda.
Read the summary - Low impact
Biocon Limited Releases Q4 FY26 Earnings Call Audio/Video Recording
Biocon Limited released the audio and video recording of its Q4 FY26 Earnings Call. The call took place on May 08, 2026. Recordings are available on the company website and a direct link is provided for investors.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio